CRYSTALLINE FORM HAVING SPECIFIC CRYSTAL HABIT AND PHARMACEUTICAL COMPOSITION CONTAINING THIS CRYSTALLINE FORM AS ACTIVE INGREDIENT

摘要

Means are provided for improving the solubility of ruliconazole. The following expression: (Ruliconazole) , Wherein the crystal has an RTI ID = 0.0 (011) / RTI Decision is _{I (001), I (100} ), I (10-1), I (011), I (110), I (11-1), I (10-2), I (11-2), _{I (020), I (021} ), I (20-2), I (121), I (013), I (11-3) and I ₍₀₁₁₎ of the total of I ₍₂₂₁₎ is at least 25% (100), (10-1), (011), (110), (11-1), (10-2), (11-2), (020) , 20-2, (121), (013), (11-3) and (221) integrated intensity of the diffraction peak corresponding to surfaces 2 θ = 5 to the powder X- ray diffractometer using the CuKα 35 ° range, respectively I ₍₀₀₁₎ with respect to the detected diffraction _{peaks, I (100), I (} 10-1), I (011), I (110), I (11-1) in, I of _{( 10-2), I (11-2),} I (020), I (021), I (20-2), I (121), I (013), I (11-3) and I ₍₂₂₁₎ As shown in FIG.